EYPT

5.42

7.03% -0.41

After Hours: 5.42

Eyepoint Pharmaceuticals Inc (EYPT)

Overview News Price History Option Chain Financials Discussions Forecast Stock Split

Eyepoint Pharmaceuticals Inc stock is traded at $5.42, with a volume of 638.00K. It is down -7.03% in the last 24 hours and down -13.56% over the past month.

Previous Close:

$5.83

Open:

$5.63

24h Volume:

638.00K

Relative Volume:

0.84

Market Cap:

$406.19M

Revenue:

$46.02M

Net Income/Loss:

$-70.80M

P/E Ratio:

-2.978

EPS:

-1.82

Net Cash Flow:

$-1.61M

1W Performance:

-14.51%

1M Performance:

-13.56%

6M Performance:

-32.17%

1Y Performance:

-73.78%

1-Day Range:

$5.34

$5.71

1-Week Range:

$5.34

$6.4811

52-Week Range:

$5.34

$23.64

Eyepoint Pharmaceuticals Inc Stock (EYPT) Company Profile

Name

Eyepoint Pharmaceuticals Inc

Sector

Healthcare (1164)

Industry

Biotechnology (681)

Phone

617-926-5000

Address

480 PLEASANT STREET, WATERTOWN, MA

Employee

Twitter

@eyepointpharma

Next Earnings Date

2025-03-05

Latest SEC Filings

EYPT's Discussions on Twitter

Compare EYPT with other stocks

Stocks	Price	Market Cap	Revenue	Net Income	Cash Flow	EPS
EYPT Eyepoint Pharmaceuticals Inc	5.42	406.19M	46.02M	-70.80M	-1.61M	-1.82
VRTX Vertex Pharmaceuticals Inc	484.82	131.41B	11.02B	-535.60M	-978.00M	-2.20
REGN Regeneron Pharmaceuticals Inc	634.23	72.26B	14.20B	4.41B	3.54B	38.28
ARGX Argen X Se Adr	591.87	36.10B	2.19B	833.04M	-1.28B	12.71
ALNY Alnylam Pharmaceuticals Inc	270.02	35.03B	2.25B	-278.16M	-42.59M	-2.17
ONC Beigene Ltd Adr	272.17	28.24B	3.81B	-644.79M	-669.77M	-6.24

Eyepoint Pharmaceuticals Inc Stock (EYPT) Upgrades & Downgrades

Date	Action	Analyst	Rating Change
Jan-07-25	Initiated	Citigroup	Buy
Oct-16-24	Initiated	Scotiabank	Sector Outperform
Aug-28-24	Initiated	Jefferies	Buy
Jan-22-24	Initiated	JP Morgan	Overweight
Nov-02-23	Initiated	Mizuho	Buy
Apr-21-23	Initiated	Robert W. Baird	Outperform
Jul-07-22	Initiated	Chardan Capital Markets	Buy
Mar-01-21	Initiated	Cowen	Outperform
Jan-28-21	Initiated	Cantor Fitzgerald	Overweight
Apr-06-20	Downgrade	B. Riley FBR	Buy → Neutral
Nov-04-19	Resumed	Laidlaw	Buy
Sep-12-19	Initiated	Guggenheim	Buy

View All

Eyepoint Pharmaceuticals Inc Stock (EYPT) Latest News

Mar 30, 2025

Long Term Trading Analysis for (EYPT) - news.stocktradersdaily.com

Mar 30, 2025

Mar 28, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Receives Average Recommendation of “Buy” from Analysts - Defense World

Mar 28, 2025

Mar 27, 2025

EyePoint to Present at 2025 RBC Capital Markets Ophthalmology Virtual Conference - The Manila Times

Mar 27, 2025

EyePoint's CEO Takes Center Stage: Key Updates Coming at RBC Ophthalmology Conference - Stock Titan

Mar 27, 2025

What is Chardan Capital’s Estimate for EYPT FY2026 Earnings? - Defense World

Mar 27, 2025

Mar 23, 2025

EyePoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Shares Bought by Bank of New York Mellon Corp - Defense World

Mar 23, 2025

Mar 20, 2025

(EYPT) Investment Report - news.stocktradersdaily.com

Mar 20, 2025

Mar 19, 2025

Mizuho maintains EyePoint stock Outperform with $30 target By Investing.com - Investing.com Australia

Mar 19, 2025

Mar 18, 2025

Mizuho maintains EyePoint stock Outperform with $30 target - Investing.com India

Mar 18, 2025

Mar 17, 2025

EyePoint Pharmaceuticals Reports Inducement Grants Under NASDAQ Listing Rule 5635(c)(4) - The Manila Times

Mar 17, 2025

Mar 14, 2025

Li Auto, Xponential Fitness And Other Big Stocks Moving Lower In Friday's Pre-Market Session - Benzinga India

Mar 14, 2025

StockNews.com Upgrades EyePoint Pharmaceuticals (NASDAQ:EYPT) to “Sell” - Defense World

Mar 14, 2025

Mar 12, 2025

EyePoint Pharmaceuticals at Leerink’s Conference: DuraView’s Promising Potential By Investing.com - Investing.com Canada

Mar 12, 2025

Mar 10, 2025

Q1 EPS Estimate for EyePoint Pharmaceuticals Cut by Analyst - Defense World

Mar 10, 2025

Research Analysts Set Expectations for EYPT FY2025 Earnings - Defense World

Mar 10, 2025

Mar 09, 2025